“Named patient supply,” also referred to as “named patient program,” or “compassionate use,” is a provision in the pharmaceutical industry that allows patients to gain access to drugs that are not yet approved in their country. Regulatory authorities in various countries oversee these programs to ensure they are conducted ethically and safely, balancing the need for access to potentially life-saving drugs with the requirement to protect patients from unproven or unsafe treatments